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Abstract
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly
1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and
links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/
doi/bph.15537. In addition to this overview, in which are identified ‘Other protein targets’ which fall outside of the subsequent categorisation, there are six areas of focus: G protein-coupled receptors, ion
channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological
tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to
mid-2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the
Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human
drug targets, where appropriate.
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Introduction
In order to allow clarity and consistency in pharmacology, there
is a need for a comprehensive organisation and presentation of
the targets of drugs. This is the philosophy of the IUPHAR/BPS
Guide to PHARMACOLOGY presented on the online free access
database (http://www.guidetopharmacology.org/). This database
is supported by the British Pharmacological Society (BPS), the In-
ternational Union of Basic and Clinical Pharmacology (IUPHAR),
the University of Edinburgh and previously the Wellcome Trust.
Data included in the Guide to PHARMACOLOGY are derived in
large part from interactions with the subcommittees of the Nomen-
clature amd Standards Committee of the International Union of
Basic and Clinical Pharmacology (NC-IUPHAR). A major influence
on the development of the database was Tony Harmar (1951-2014),
who worked with a passion to establish the curators as a team
of highly informed and informative individuals, with a focus on
high-quality data input, ensuring a suitably validated dataset. The
Editors of the Concise Guide have compiled the individual records,
in concert with the team of Curators, drawing on the expert knowl-
edge of these latter subcommittees. The tables allow an indication
of the status of the nomenclature for the group of targets listed,
usually previously published in Pharmacological Reviews. In the
absence of an established subcommittee, advice from several
prominent, independent experts has generally been obtained to
produce an authoritative consensus on nomenclature, which at-
tempts to fit in within the general guidelines from NC-IUPHAR.
This current edition, the Concise Guide to PHARMACOLOGY
2021/22, is the latest snapshot of the database in print form, fol-
lowing on from the Concise Guide to PHARMACOLOGY 2019/20.
It contains data drawn from the online database as a rapid overview
of the major pharmacological targets. Thus, there are many fewer
targets presented in the Concise Guide compared to the online
database. The priority for inclusion in the Concise Guide is the
presence of quantitative pharmacological data for human proteins.
This means that often orphan family members are not presented
in the Concise Guide, although structural information is available
on the online database. The organisation of the data is tabular
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(where appropriate) with a standardised format, where possible on
a single page, intended to aid understanding of, and comparison
within, a particular target group. The Concise Guide is intended as
an initial resource, with links to additional reviews and resources
for greater depth and information. Pharmacological and structural
data focus primarily on human gene products, wherever possible,
with links to HGNC gene nomenclature and UniProt IDs. In a few
cases, where data from human proteins are limited, data from other
species are indicated. Pharmacological tools listed are prioritised
on the basis of selectivity and availability. That is, agents (agonists,
antagonists, inhibitors, activators, etc.) are included where they
are both available (by donation or from commercial sources, now
or in the near future) AND the most selective. The Concise Guide is
divided into seven sections, which comprise pharmacological tar-
gets of similar structure/function. These are G protein-coupled re-
ceptors, ion channels (combining previous records of ligand-gated,
voltage-gated and other ion channels), catalytic receptors, nuclear
hormone receptors, enzymes, transporters and other protein tar-
gets. We hope that the Concise Guide will provide for researchers,
teachers and students a state-of-the art source of accurate, curated
information on the background to their work that they will use in
the Introductions to their Research Papers or Reviews, or in sup-
porting their teaching and studies. We recommend that any ci-
tations to information in the Concise Guide are presented in the
following format:
Alexander SPH et al. (2021). The Concise Guide to PHARMACOL-
OGY 2021/22: Overview. Br J Pharmacol 178: S1–S26.
In this overview are listed protein targets of pharmacological in-
terest, which are not G protein-coupled receptors, ion channels,
nuclear hormone receptors, catalytic receptors, transporters or en-
zymes. For obvious reasons, we have included potential drug tar-
gets of the SARS-CoV-2 virus, despite the current limited pharma-
cological data.
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Family structure




– Other anti-infective targets
S9 Aryl hydrocarbon receptor
– B-cell lymphoma 2 (Bcl-2) protein
family
– Bromodomain-containing proteins
S10 Non-enzymatic BRD containing proteins




– Lipid binding chaperones
– Chitinase-like proteins
– Chromatin-interacting transcriptional repressors
S13 Methyllysine reader proteins
– Circadian clock proteins
– Claudins
– Cytolytic pore-forming proteins
– EF-hand domain containing proteins
S14 Fatty acid-binding proteins
– Guanine nucleotide exchange factors
(GEFs)
– Heat shock proteins
– Hypoxia-inducible factors





– Immunoglobulin like domain
containing proteins
– Immunoglobulins




– Leucine-rich repeat proteins
– Lymphocyte antigens
– Mitochondrial-associated proteins
– Myosin binding proteins
– Neuropilins and Plexins
– Non-catalytic pattern recognition
receptors
S16 Notch receptors
– Nuclear export proteins
– Pentraxins






– Repulsive guidance molecules
– Reticulons and associated proteins
– Ribosomal factors
– Sialic acid binding Ig like lectins
S20 Sigma receptors
– Signal regulatory proteins
– Tetraspanins
– Transcription factors





– WD repeat-containing proteins





S25 Nucleic acid turnover
S25 Other proteins
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Adiponectin receptors
Other protein targets → Adiponectin receptors
Overview: Adiponectin receptors (provisional
nomenclature, ENSFM00500000270960) respond to the 30
kDa complement-related protein hormone adiponectin (also
known as ADIPOQ: adipocyte, C1q and collagen
domain-containing protein; ACRP30, adipose most abundant
gene transcript 1; apM-1; gelatin-binding protein: Q15848)
originally cloned from adipocytes [69]. Although sequence data
suggest 7TM domains, immunological evidence indicates that,
contrary to typical 7TM topology, the carboxyl terminus is
extracellular, while the amino terminus is intracellular [136].
Signalling through these receptors appears to avoid G proteins;
modelling based on the crystal structures of the adiponectin
receptors suggested ceramidase acivity, which would make these
the first in a new family of catalytic receptors [121].
Further reading on Adiponectin receptors
Fisman EZ et al. (2014) Adiponectin: a manifold therapeutic target for metabolic syndrome,
diabetes, and coronary disease? Cardiovasc Diabetol 13: 103 [PMID:24957699]
Okada-Iwabu M et al. (2018) Structure and function analysis of adiponectin receptors toward
development of novel antidiabetic agents promoting healthy longevity. Endocr J 65: 971-977
[PMID:30282888]
Ruan H et al. (2016) Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol 8:
101-9 [PMID:26993044]
Wang Y et al. (2017) Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin
Receptor Modification. Trends Endocrinol Metab 28: 519-530 [PMID:28473178]
Zhao L et al. (2014) Adiponectin and insulin cross talk: the microvascular connection. Trends
Cardiovasc Med 24: 319-24 [PMID:25220977]
Nomenclature Adipo1 receptor Adipo2 receptor
HGNC, UniProt ADIPOR1, Q96A54 ADIPOR2, Q86V24
Rank order of potency globular adiponectin (ADIPOQ, Q15848) > adiponectin (ADIPOQ,
Q15848)
globular adiponectin (ADIPOQ, Q15848) = adiponectin (ADIPOQ,
Q15848)
Comments: T-Cadherin (CDH13, P55290) has also been suggested to be a receptor for (hexameric) adiponectin [47].
Searchable database: http://www.guidetopharmacology.org/index.jsp Adiponectin receptors S8
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Aryl hydrocarbon receptor
Other protein targets → Aryl hydrocarbon receptor
Overview: The aryl hydrocarbon receptor, highly expressed in
the liver and barrier organs, is resident in the cytoplasm bound
to the chaperone heat shock protein hsp90. Upon agonist
activation, the ligand:aryl hydrocarbon receptor complex
migrates to the nucleus and binds the aryl hydrocarbon receptor
nuclear translocator (ARNT, P27540, also known as HIF1β). The
complex regulates transcription of selected genes through
interaction with xenobiotic response elements (XRE). Among the
genes regulated by the AHR/ARNT complex are cytochrome
P450s, particularly CYP1A1, and the period circadian protein
homolog 1 (PER1, O15534). The aryl hydrocarbon receptor is
also capable of non-genomic signalling.
Further reading on Aryl hydrocarbon receptor
Bock KW. (2019) Aryl hydrocarbon receptor (AHR): From selected human target genes and
crosstalk with transcription factors to multiple AHR functions. Biochem Pharmacol 168: 65-70
[PMID:31228464]
Bock KW. (2020) Aryl hydrocarbon receptor (AHR) functions: Balancing opposing processes
including inflammatory reactions. Biochem Pharmacol 178: 114093 [PMID:32535108]
Esser C et al. (2015) The aryl hydrocarbon receptor in barrier organ physiology, immunology, and
toxicology. Pharmacol Rev 67: 259-79 [PMID:25657351]
Roman ÁC et al. (2018) The aryl hydrocarbon receptor in the crossroad of signalling networks
with therapeutic value. Pharmacol Ther 185: 50-63 [PMID:29258844]
Rothhammer V et al. (2019) The aryl hydrocarbon receptor: an environmental sensor integrating
immune responses in health and disease. Nat Rev Immunol 19: 184-197 [PMID:30718831]
Shi Y et al. (2020) The aryl hydrocarbon receptor: An environmental effector in the pathogenesis
of fibrosis. Pharmacol Res 160: 105180 [PMID:32877693]
Nomenclature Aryl hydrocarbon receptor
HGNC, UniProt AHR, P35869
Agonists indolo[3,2-b]carbazole [12] – Mouse, tapinarof [110], indole-3-carbinol [12] – Mouse, TCDD
Antagonists ezutromid (pKd 7.3) [132]
Searchable database: http://www.guidetopharmacology.org/index.jsp Aryl hydrocarbon receptor S9
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Non-enzymatic BRD containing proteins
Other protein targets → Bromodomain-containing proteins → Non-enzymatic BRD containing proteins
Overview: Bromodomains bind proteins with acetylated lysine residues, such as histones, to regulate gene transcription. Listed herein are examples of bromodomain-containing proteins for which
sufficient pharmacology exists.
Further reading on Non-enzymatic BRD containing proteins
Fujisawa T et al. (2017) Functions of bromodomain-containing proteins and their roles in
homeostasis and cancer. Nat Rev Mol Cell Biol 18: 246-262 [PMID:28053347]
Myrianthopoulos V et al. (2019) From bench to bedside, via desktop. Recent advances in the
application of cutting-edge in silico tools in the research of drugs targeting bromodomain
modules. Biochem Pharmacol 159: 40-51 [PMID:30414936]
Nicholas DA et al. (2017) BET bromodomain proteins and epigenetic regulation of inflammation:
implications for type 2 diabetes and breast cancer. Cell Mol Life Sci 74: 231-243
[PMID:27491296]
Ramadoss M et al. (2018) Targeting the cancer epigenome: synergistic therapy with bromodomain
inhibitors. Drug Discov Today 23: 76-89 [PMID:28943305]
Spriano F et al. (2020) Targeting BET bromodomain proteins in cancer: The example of
lymphomas. Pharmacol Ther 215: 107631 [PMID:32693114]
Tang P et al. (2021) Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From
Current Progress to Technological Development. J Med Chem 64: 2419-2435 [PMID:33616410]
Nomenclature bromodomain adjacent to zinc
finger domain 2A
bromodomain adjacent to zinc
finger domain 2B
CREB binding protein polybromo 1 SWI/SNF related, matrix
associated, actin dependent
regulator of chromatin,
subfamily a, member 4
HGNC, UniProt BAZ2A, Q9UIF9 BAZ2B, Q9UIF8 CREBBP, Q92793 PBRM1, Q86U86 SMARCA4, P51532
Selective inhibitors GSK2801 (pKd 6.6) [87] GSK2801 (Binding)
(pKd 6.9) [87]
I-CBP112 (pKd 6.8) [88] PFI-3 (Binding) (pKd 7.3) [101] PFI-3 (Binding) (pKd 7.1) [101]
Searchable database: http://www.guidetopharmacology.org/index.jsp Non-enzymatic BRD containing proteins S10
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CD molecules
Other protein targets → CD molecules
Overview: Cluster of differentiation refers to an attempt to
catalogue systematically a series of over 300 cell-surface proteins
associated with immunotyping. Many members of the group
have identified functions as enzymes (for example, see CD73
ecto-5’-nucleotidase) or receptors (for example, see CD41
integrin, alpha 2b subunit). Many CDs are targeted for
therapeutic gain using antibodies for the treatment of
proliferative disorders. A full listing of all the Clusters of
Differentiation proteins is not possible in the Guide to
PHARMACOLOGY; listed herein are selected members of the
family targeted for therapeutic gain.
Further reading on CD molecules
Bewersdorf JP et al. (2021) Immune checkpoint inhibition in myeloid malignancies: Moving
beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Rev 45: 100709 [PMID:32487480]
Chi Z et al. (2021) Transcriptional and epigenetic regulation of PD-1 expression. Cell Mol Life Sci
78: 3239-3246 [PMID:33738533]
Gabius HJ et al. (2015) The glycobiology of the CD system: a dictionary for translating marker
designations into glycan/lectin structure and function. Trends Biochem Sci 40: 360-76
[PMID:25981696]
Huang MY et al. (2021) Combination therapy with PD-1/PD-L1 blockade in non-small cell lung
cancer: strategies and mechanisms. Pharmacol Ther 219: 107694 [PMID:32980443]
Vosoughi T et al. (2019) CD markers variations in chronic lymphocytic leukemia: New insights
into prognosis. J Cell Physiol 234: 19420-19439 [PMID:31049958]
Nomenclature CD2 CD3e CD6 CD20 (membrane-spanning 4-domains,




– – – – SIGLEC3
HGNC, UniProt CD2, P06729 CD3E, P07766 CD6, P30203 MS4A1, P11836 CD33, P20138
Selective inhibitors alefacept [23, 74] – – – –
Antibodies – catumaxomab (Binding) [63],
muromonab-CD3 (Binding) [32],
otelixizumab (Binding) [14]
– ofatumumab (Binding) (pKd 9.9) [58],
rituximab (Binding) (pKd 8.5) [113],
ibritumomab tiuxetan (Binding),
obinutuzumab (Binding) [3, 90],
tositumomab (Binding)
lintuzumab (Binding) (pKd ∼10) [16],
gemtuzumab ozogamicin (Binding) [10]
Searchable database: http://www.guidetopharmacology.org/index.jsp CD molecules S11
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Nomenclature CD52 CD80 CD86 cytotoxic
T-lymphocyte-associated
protein 4 (CD152)
programmed cell death 1
(CD279)
CD300a
Common abbreviation – – – CTLA-4 PD-1 –
HGNC, UniProt CD52, P31358 CD80, P33681 CD86, P42081 CTLA4, P16410 PDCD1, Q15116 CD300A, Q9UGN4
Endogenous ligands – – – – programmed cell death 1
ligand 1 (CD274, Q9NZQ7)
(Binding)
–
Selective inhibitors – abatacept (pKd ∼7.9)
[64, 125]
abatacept (pKd ∼7.9)




– – ipilimumab (Binding) (pKd
>9) [33], tremelimumab
(Binding) (pKd 8.9) [35]
pembrolizumab (Binding)




Comments: The endogenous ligands for human PD-1 are programmed cell death 1 ligand 1 (PD-L1 aka CD274 (CD274, Q9NZQ7)) and programmed cell death 1 ligand 2 (PD-L2; PDCD1LG2). These
ligands are cell surface peptides, normally involved in immune system regulation. Expression of PD-1 by cancer cells induces immune tolerance and evasion of immune system attack. Anti-PD-1
monoclonal antibodies are used to induce immune checkpoint blockade as a therapeutic intervention in cancer, effectively re-establishing immune vigilance. Pembrolizumab was the first anti-PD-1
antibody to be approved by the US FDA.
Searchable database: http://www.guidetopharmacology.org/index.jsp CD molecules S12
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Methyllysine reader proteins
Other protein targets → Chromatin-interacting transcriptional repressors → Methyllysine reader proteins
Overview: Methyllysine reader proteins bind to methylated proteins, such as histones, allowing regulation of gene expression.
Further reading on Methyllysine reader proteins
Daskalaki MG et al. (2018) Histone methylation and acetylation in macrophages as a mechanism
for regulation of inflammatory responses. J Cell Physiol 233: 6495-6507 [PMID:29574768]
Furuya K et al. (2019) Epigenetic interplays between DNA demethylation and histone methylation
for protecting oncogenesis. J Biochem 165: 297-299 [PMID:30605533]
Levy D. (2019) Lysine methylation signaling of non-histone proteins in the nucleus. Cell Mol Life
Sci 76: 2873-2883 [PMID:31123776]
Li J et al. (2019) Understanding histone H3 lysine 36 methylation and its deregulation in disease.
Cell Mol Life Sci 76: 2899-2916 [PMID:31147750]
Shafabakhsh R et al. (2019) Role of histone modification and DNA methylation in signaling
pathways involved in diabetic retinopathy. J Cell Physiol 234: 7839-7846 [PMID:30515789]
Nomenclature L3MBTL histone methyl-lysine binding protein 3
HGNC, UniProt L3MBTL3, Q96JM7
Selective agonists UNC1215 [50]
Searchable database: http://www.guidetopharmacology.org/index.jsp Methyllysine reader proteins S13
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Fatty acid-binding proteins
Other protein targets → Fatty acid-binding proteins
Overview: Fatty acid-binding proteins are low molecular weight
(100-130 aa) chaperones for long chain fatty acids, fatty acyl CoA
esters, eicosanoids, retinols, retinoic acids and related
metabolites and are usually regarded as being responsible for
allowing the otherwise hydrophobic ligands to be mobile in
aqueous media. These binding proteins may perform functions
extracellularly (e.g. in plasma) or transport these agents; to the
nucleus to interact with nuclear receptors (principally PPARs and
retinoic acid receptors [99]) or for interaction with metabolic
enzymes. Although sequence homology is limited,
crystallographic studies suggest conserved 3D structures across
the group of binding proteins.
Further reading on Fatty acid-binding proteins
Gajda AM et al. (2015) Enterocyte fatty acid-binding proteins (FABPs): different functions of liver
and intestinal FABPs in the intestine. Prostaglandins Leukot Essent Fatty Acids 93: 9-16
[PMID:25458898]
Glatz JF. (2015) Lipids and lipid binding proteins: a perfect match. Prostaglandins Leukot Essent
Fatty Acids 93: 45-9 [PMID:25154384]
Hotamisligil GS et al. (2015) Metabolic functions of FABPs–mechanisms and therapeutic
implications. Nat Rev Endocrinol 11: 592-605 [PMID:26260145]
Matsumata M et al. (2016) Fatty acid binding proteins and the nervous system: Their impact on
mental conditions. Neurosci Res 102: 47-55 [PMID:25205626]
Nguyen HC et al. (2020) Role of the Fatty Acid Binding Proteins in Cardiovascular Diseases: A
Systematic Review. J Clin Med 9: [PMID:33105856]
Osumi T et al. (2016) Heart lipid droplets and lipid droplet-binding proteins: Biochemistry,
physiology, and pathology. Exp Cell Res 340: 198-204 [PMID:26524506]
Nomenclature fatty acid binding protein 1 fatty acid binding protein 2 fatty acid binding protein 3 fatty acid binding protein 4 fatty acid binding protein 5
HGNC, UniProt FABP1, P07148 FABP2, P12104 FABP3, P05413 FABP4, P15090 FABP5, Q01469
Rank order of
potency
stearic acid, oleic acid > palmitic acid, linoleic acid >
arachidonic acid, α-linolenic acid [91]
stearic acid > palmitic acid,oleic
acid > linoleic acid > arachidonic
acid, α-linolenic acid [91]
stearic acid, oleic acid, palmitic
acid > linoleic acid, α-linolenic
acid, arachidonic acid [91]
oleic acid, palmitic acid, stearic
acid, linoleic acid > α-linolenic
acid, arachidonic acid [91]
–
Inhibitors fenofibrate (pKi 7.6) [18] – Rat, fenofibric acid (pKi
6.5) [18] – Rat, HTS01037 (pKi 5.1) [42] – Mouse
– – – compound 13 (pKi 8.7) [118]
Selective
inhibitors
– – – HM50316 (pKi >9) [66] –
Comments A broader substrate specificity than other FABPs,
binding two fatty acids per protein [123].
Crystal structure of the rat FABP2
[95].
Crystal structure of the human
FABP3 [137].
– Crystal structure of the human
FABP5 [44].
Searchable database: http://www.guidetopharmacology.org/index.jsp Fatty acid-binding proteins S14
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Nomenclature fatty acid binding protein 6 fatty acid binding protein 7 peripheral myelin protein 2 fatty acid binding protein 9 fatty acid binding protein 12
HGNC, UniProt FABP6, P51161 FABP7, O15540 PMP2, P02689 FABP9, Q0Z7S8 FABP12, A6NFH5
Comments Able to transport bile acids [142]. Crystal structure of the human
FABP7 [9].
In silico modelling suggests that PMP2/FABP8 can
bind both fatty acids and cholesterol [70].
– –
Nomenclature retinol binding protein 1 retinol binding protein 2 retinol binding protein 3 retinol binding protein 4 retinol binding protein 5 retinol binding protein 7
HGNC, UniProt RBP1, P09455 RBP2, P50120 RBP3, P10745 RBP4, P02753 RBP5, P82980 RBP7, Q96R05
Rank order of
potency
– stearic acid > palmitic acid, oleic acid, linoleic
acid, α-linolenic acid, arachidonic acid [92]
– – – –
Inhibitors – – – A1120 (pIC50 7.8)
[128]
– –
Nomenclature retinaldehyde binding protein 1 cellular retinoic acid binding protein 1 cellular retinoic acid binding protein 2
HGNC, UniProt RLBP1, P12271 CRABP1, P29762 CRABP2, P29373
Rank order of
potency
11-cis-retinal, 11-cis-retinol > 9-cis-retinal, 13-cis-retinal,
13-cis-retinol, all-trans-retinal, retinol [22]
tretinoin > alitretinoin
stearic acid > palmitic acid, oleic acid, linoleic acid, α-linolenic acid, arachidonic acid [92]
–
Comments: Although not tested at all FABPs, BMS309403 exhibits high affinity for FABP4 (pIC50 8.8) compared to FABP3 or FABP5 (pIC50 <6.6) [27, 118]. HTS01037 is reported to interfere with
FABP4 action [42]. Ibuprofen displays some selectivity for FABP4 (pIC50 5.5) relative to FABP3 (pIC50 3.5) and FABP5 (pIC50 3.8) [68]. Fenofibric acid displays some selectivity for FABP5 (pIC50 5.5)
relative to FABP3 (pIC50 4.5) and FABP4 (pIC50 4.6) [68]. Multiple pseudogenes for the FABPs have been identified in the human genome.
Searchable database: http://www.guidetopharmacology.org/index.jsp Fatty acid-binding proteins S15
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Notch receptors
Other protein targets → Notch receptors
Overview: Aberrant Notch signalling is implicated in a number of human cancers [59, 80, 108, 126], and there is intense pharmaceutical activity being directed towards achieving clinically effective
Notch pathway inhibition [24, 75].
Further reading on Notch receptors
Fabbro D et al. (2020) Notch Inhibition in Cancer: Challenges and Opportunities. Chimia (Aarau)
74: 779-783 [PMID:33115560]
Moore G et al. (2020) Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent
Insights and Current Perspectives. Cells 9: [PMID:32575680]
Palmer WH et al. (2015) Ligand-Independent Mechanisms of Notch Activity. Trends Cell Biol 25:
697-707 [PMID:26437585]
Previs RA et al. (2015) Molecular pathways: translational and therapeutic implications of the
Notch signaling pathway in cancer. Clin Cancer Res 21: 955-61 [PMID:25388163]
Takebe N et al. (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical
update. Nat Rev Clin Oncol 12: 445-64 [PMID:25850553]
Nomenclature notch receptor 1 notch receptor 2 notch receptor 3 notch receptor 4
HGNC, UniProt NOTCH1, P46531 NOTCH2, Q04721 NOTCH3, Q9UM47 NOTCH4, Q99466
Inhibitors IMR-1 (Binding) (pKd 5) [8] – – –





Comments Various types of activating and inactivating NOTCH1 mutations have been reported to be associated with
human diseases, for example: aortic valve disease [29, 73], Adams-Oliver syndrome 5 [114], T-cell acute
lymphoblastic leukemia (T-ALL) [130], chronic lymphocytic leukemia (CLL) [89] and head and neck
squamous cell carcinoma [1, 115].
– – Notch receptor 4 is a potential
therapeutic molecular target for
triple-negative breast cancer [60,
77].
Searchable database: http://www.guidetopharmacology.org/index.jsp Notch receptors S16
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Regulators of G protein Signaling (RGS) proteins
Other protein targets → Regulators of G protein Signaling (RGS) proteins
Overview: Regulator of G protein Signaling, or RGS, proteins
serve an important regulatory role in signaling mediated by G
protein-coupled receptors (GPCRs). They all share a common
RGS domain that directly interacts with active, GTP-bound Gα
subunits of heterotrimeric G proteins. RGS proteins stabilize the
transition state for GTP hydrolysis on Gα and thus induce a
conformational change in the Gα subunit that accelerates GTP
hydrolysis, thereby effectively turning off signaling cascades
mediated by GPCRs. This GTPase accelerating protein (GAP)
activity is the canonical mechanism of action for RGS proteins,
although many also possess additional functions and domains.
RGS proteins are divided into four families, R4, R7, R12 and RZ
based on sequence homology, domain structure as well as
specificity towards Gα subunits. For reviews on RGS proteins and
their potential as therapeutic targets, see e.g. [5, 45, 79, 93, 105,
106, 107, 138, 140].
Further reading on Regulators of G protein Signaling (RGS) proteins
Alqinyah M et al. (2018) Regulating the regulators: Epigenetic, transcriptional, and
post-translational regulation of RGS proteins. Cell Signal 42: 77-87 [PMID:29042285]
Fuentes N et al. (2021) RGS proteins, GRKs, and beta-arrestins modulate G protein-mediated
signaling pathways in asthma. Pharmacol Ther 223: 107818 [PMID:33600853]
Neubig RR et al. (2002) Regulators of G-protein signalling as new central nervous system drug
targets. Nat Rev Drug Discov 1: 187-97 [PMID:12120503]
Sethakorn N et al. (2010) Non-canonical functions of RGS proteins. Cell Signal 22: 1274-81
[PMID:20363320]
Sjögren B. (2017) The evolution of regulators of G protein signalling proteins as drug targets - 20
years in the making: IUPHAR Review 21. Br J Pharmacol 174: 427-437 [PMID:28098342]
Sjögren B et al. (2010) Thinking outside of the "RGS box": new approaches to therapeutic targeting
of regulators of G protein signaling. Mol Pharmacol 78: 550-7 [PMID:20664002]
RZ family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → RZ family
Overview: The RZ family of RGS proteins is less well
characterized than the other families. It consists of, RGS17 (also
known as RGSZ2), RGS19 (also known as GAIP) and RGS20 (with
several splice variants including RGSZ1 and Ret-RGS). All
members contain an N-terminal cysteine string motif [62] which
is a site of palmitoylation and could serve functions in
membrane targeting, protein stability or aid protein-protein
interactions [2, 62]. However, the function in the case of RZ
family RGS proteins is not yet fully understood. Members of the
RZ family of RGS proteins are the only RGS proteins that have
selective GAP activity for Gαz, a function that resulted in the
name of the family [31, 71, 127, 134]. However, the members of
the RZ family are able to also GAP Gαi/o members with varying
selectivity.
Nomenclature regulator of G-protein signaling 17 regulator of G-protein signaling 19 regulator of G-protein signaling 20
Common abbreviation RGS17 RGS19 RGS20
HGNC, UniProt RGS17, Q9UGC6 RGS19, P49795 RGS20, O76081
Searchable database: http://www.guidetopharmacology.org/index.jsp RZ family S17
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R4 family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → R4 family
Overview: The R4 family of RGS proteins is the largest family of
RGS proteins with 10 members. Each of the R4 family members
contain only small N- and C-termini apart from the RGS domain.
The N-terminal amphipathic helix present in most R4 family
members serves an important function in membrane association
and can directly bind phospholipids. In contrast to the RGS
domain, which is well conserved among members of the R4
family of RGS proteins, the N- and C-termini vary, enabling
specificity of non-GAP functions. Despite the non-complex
structure of these proteins, several R4 family RGS proteins have
been shown to possess additional functions apart from acting as
GAPs at activated Gα subunits [11, 96].
Further reading on R4 family
Xie Z et al. (2016) R4 Regulator of G Protein Signaling (RGS) Proteins in Inflammation and
Immunity. AAPS J 18: 294-304 [PMID:26597290]
Nomenclature regulator of G-protein signaling 1 regulator of G-protein signaling 2 regulator of G-protein signaling 3 regulator of G-protein signaling 4
Common abbreviation RGS1 RGS2 RGS3 RGS4
HGNC, UniProt RGS1, Q08116 RGS2, P41220 RGS3, P49796 RGS4, P49798
Selective inhibitors – – – RGS4 inhibitor 11b (pIC50 7.8) [124],
CCG-50014 (pIC50 7.5) [13, 124], RGS4
inhibitor 13 (pIC50 7.3) [124]












Common abbreviation RGS5 RGS8 RGS13 RGS16 RGS18 RGS21
HGNC, UniProt RGS5, O15539 RGS8, P57771 RGS13, O14921 RGS16, O15492 RGS18, Q9NS28 RGS21, Q2M5E4
Searchable database: http://www.guidetopharmacology.org/index.jsp R4 family S18
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R7 family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → R7 family
Overview: The members of the R7 family of RGS proteins [6]
are more complex structures than the R4 family and are closely
related to the C. elegans homologues EGL-10 and EAT-16 that
were identified in the early stage of RGS protein research [36, 55].
Apart from the RGS domain, several additional domains are
present in these proteins that mediate protein-protein
interactions, sub-cellular localization and protein stability. All R7
family members form obligatory dimers with Gβ5 through the
G-γ like (GGL) domain and the disheveled-EGL10-Pleckstrin
homology (DEP) domain [109]. The DEP and DEP helical
extension domain interact with R7 binding protein (R7BP) or
RGS9 anchoring protein (R9AP; in retina) that serves as a plasma
membrane anchoring mechanism [41, 51].
Nomenclature regulator of G-protein signaling 6 regulator of G-protein signaling 7 regulator of G-protein signaling 9 regulator of G-protein signaling 11
Common abbreviation RGS6 RGS7 RGS9 RGS11
HGNC, UniProt RGS6, P49758 RGS7, P49802 RGS9, O75916 RGS11, O94810
R12 family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → R12 family
Overview: The R12 family consisting of RGS10, 12 and 14.
RGS12 and 14 are large proteins with additional domains that
can participate in protein-protein interactions and other
functions. In contrast, RGS10 is a small protein consisting of the
RGS domain and small N- and C-termini, similar to members of
the R4 family. However, the sequence homology the RGS10 RGS
domain clearly places it in the R12 family [58]. The Gαi/o-Loco
(GoLoco) motif in RGS12 and 14 has GDI activity (for Guanine
nucleotide Dissociation Inhibitor) towards Gαi1, Gαi2 and Gαi3
[53, 105]. Through this activity RGS12 and RGS14 can inhibit G
protein signaling both by accelerating GTP hydrolysis and by
preventing G protein activation. Splice variants of RGS12 and
RGS14 also contain membrane targeting and protein-protein
interaction domains [97, 111, 112].
Nomenclature regulator of G-protein signaling 10 regulator of G-protein signaling 12 regulator of G-protein signaling 14
Common abbreviation RGS10 RGS12 RGS14
HGNC, UniProt RGS10, O43665 RGS12, O14924 RGS14, O43566
Searchable database: http://www.guidetopharmacology.org/index.jsp R12 family S19
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Sigma receptors
Other protein targets → Sigma receptors
Overview: Although termed ’receptors’, the evidence for coupling through conventional signalling pathways is lacking. Initially described as a subtype of opioid receptors, there is only a modest
pharmacological overlap and no structural convergence with the G protein-coupled receptors; the crystal structure of the sigma1 receptor [98] suggests a trimeric structure of a single short
transmembrane domain traversing the endoplasmic reticulum membrane, with the bulk of the protein facing the cytosol. A wide range of compounds, ranging from psychoactive agents to
antihistamines, have been observed to bind to these sites.
Further reading on Sigma receptors
Chu UB et al. (2016) Biochemical Pharmacology of the Sigma-1 Receptor. Mol Pharmacol 89:
142-53 [PMID:26560551]
Herrando-Grabulosa M et al. (2021) Sigma 1 receptor as a therapeutic target for amyotrophic
lateral sclerosis. Br J Pharmacol 178: 1336-1352 [PMID:32761823]
Sambo DO et al. (2018) The sigma-1 receptor as a regulator of dopamine neurotransmission: A
potential therapeutic target for methamphetamine addiction. Pharmacol Ther 186: 152-167
[PMID:29360540]
Schmidt HR et al. (2019) The Molecular Function of σ Receptors: Past, Present, and Future. Trends
Pharmacol Sci 40: 636-654 [PMID:31387763]
Su TP et al. (2016) The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends
Pharmacol Sci 37: 262-278 [PMID:26869505]
Vavers E et al. (2019) Allosteric Modulators of Sigma-1 Receptor: A Review. Front Pharmacol 10:
223 [PMID:30941035]
Nomenclature sigma non-opioid intracellular receptor 1 σ2
HGNC, UniProt SIGMAR1, Q99720 TMEM97, Q5BJF2
Agonists – 1,3-ditolylguanidine [61] – Guinea pig
Selective agonists PRE-084 [117], (+)-SKF 10.047 –
Antagonists – SM 21 (pIC50 7.2) [67]
Selective antagonists NE-100 (pIC50 8.4) [81], BD-1047 (pIC50 7.4) [72] –
Labelled ligands [3H]pentazocine (Agonist) [3H]-di-o-tolylguanidine (Agonist)
Comments – The sigma2 receptor has been reported to be TMEM97 [4], a 4TM
protein partner of NPC1, the Niemann-Pick C1 protein, a 13TM
cholesterol-binding protein.
Comments: (-)-pentazocine also shows activity at opioid receptors. The sigma2 receptor has recently been reported to be TMEM97 [4], a 4TM protein partner of NPC1, the Niemann-Pick C1 protein, a
13TM cholesterol-binding protein.
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Transthyretin
Other protein targets → Transthyretin
Overview: Transthyretin (TTR) is a homo-tetrameric protein
which transports thyroxine in the plasma and cerebrospinal fluid
and retinol (vitamin A) in the plasma. Many disease causing
mutations in the protein have been reported, many of which
cause complex dissociation and protein mis-assembly and
deposition of toxic aggregates amyloid fibril formation [84].
These amyloidogenic mutants are linked to the development of
pathological amyloidoses, including familial amyloid
polyneuropathy (FAP) [7, 20], familial amyloid cardiomyopathy
(FAC) [49], amyloidotic vitreous opacities, carpal tunnel
syndrome [76] and others. In old age, non-mutated TTR can also
form pathological amyloid fibrils [131]. Pharmacological
intervention to reduce or prevent TTR dissociation is being
pursued as a therapeutic strategy. To date one small molecule
kinetic stabilising molecule (tafamidis) has been approved for
FAP, and is being evaluated in clinical trials for other TTR
amyloidoses.
Further reading on Transthyretin
Adams D et al. (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal
disease. Nat Rev Neurol 15: 387-404 [PMID:31209302]
Bezerra F et al. (2020) Modulation of the Mechanisms Driving Transthyretin Amyloidosis. Front
Mol Neurosci 13: 592644 [PMID:33362465]
Dohrn MF et al. (2020) Targeting transthyretin - Mechanism-based treatment approaches and
future perspectives in hereditary amyloidosis. J Neurochem [PMID:33155274]
Galant NJ et al. (2017) Transthyretin amyloidosis: an under-recognized neuropathy and
cardiomyopathy. Clin Sci 131: 395-409 [PMID:28213611]
Griffin JM et al. (2019) Transthyretin cardiac amyloidosis: A treatable form of heart failure with a
preserved ejection fraction. Trends Cardiovasc Med [PMID:31889610]
Nomenclature transthyretin
Common abbreviation TTR
HGNC, UniProt TTR, P02766
Inhibitors tafamidis (pKd 8.7) [15]
Comments: Excess production and accumulation of TTR causes
hereditary transthyretin-mediated amyloidosis. Two novel drugs
are now approved to combat this disease: inotersen (Tegsedi®)
[52] and patisiran (Onpattro®) [46]. Both of these drugs act to
reduce the amount of TTR protein (both wild type and mutant)
produced in the liver, but by slightly different mechanisms.
Inotersen is an antisense oligonucleotide inhibitor of TTR
synthesis, whereas patisiran is a double-stranded small
interfering RNA (which targets a conserved sequence in the 3’
UTR of mutant and wild-type TTR mRNA). Inotersen is
administered subcutaneously, and patisiran is delivered by
intravenous infusion in a lipid nanoparticle formulation.
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Tubulins
Other protein targets → Tubulins
Overview: Tubulins are a family of intracellular proteins most commonly associated with microtubules, part of the cytoskeleton. They are exploited for therapeutic gain in cancer chemotherapy as
targets for agents derived from a variety of natural products: taxanes, colchicine and vinca alkaloids. These are thought to act primarily through β-tubulin, thereby interfering with the normal processes
of tubulin polymer formation and disassembly.
Further reading on Tubulins
Arnst KE et al. (2019) Current advances of tubulin inhibitors as dual acting small molecules for
cancer therapy. Med Res Rev 39: 1398-1426 [PMID:30746734]
Boiarska Z et al. (2021) Microtubule-targeting agents and neurodegeneration. Drug Discov Today
26: 604-615 [PMID:33279455]
Eshun-Wilson L et al. (2019) Effects of α-tubulin acetylation on microtubule structure and
stability. Proc Natl Acad Sci USA 116: 10366-10371 [PMID:31072936]
Gadadhar S et al. (2017) The tubulin code at a glance. J Cell Sci 130: 1347-1353 [PMID:28325758]
Magiera MM et al. (2018) Tubulin Posttranslational Modifications and Emerging Links to Human
Disease. Cell 173: 1323-1327 [PMID:29856952]
Penna LS et al. (2017) Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Pharmacol Ther 173: 67-82 [PMID:28174095]
Nomenclature tubulin alpha 1a tubulin alpha 4a tubulin beta class I tubulin beta 3 class III tubulin beta 4B class IVb tubulin beta 8 class VIII
HGNC, UniProt TUBA1A, Q71U36 TUBA4A, P68366 TUBB, P07437 TUBB3, Q13509 TUBB4B, P68371 TUBB8, Q3ZCM7
Inhibitors – – vinblastine (pIC50 9), eribulin (pIC50 8.2) [78], paclitaxel (Mitotic cell
cycle arrest in A431 cells) (pEC50 8.1) [83], colchicine (pIC50 8) [19],
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SARS-CoV-2
Other protein targets → SARS-CoV-2
Coronaviruses are large, often spherical, enveloped, single-stranded positive-sense RNA viruses, ranging in size from 80–220 nm. Their genomes and protein structures are highly conserved. Three
coronaviruses have emerged over the last 20 years as serious human pathogens: SARS-CoV was identified as the causative agent in an outbreak in 2002–2003, Middle East respiratory syndrome (MERS)
CoV emerged in 2012 and the novel coronavirus SARS-CoV-2 emerged in 2019–2020. SARS-CoV-2 is the virus responsible for the infectious disease termed COVID-19 (WHO Technical Guidance 2020).
Further reading on Tubulins
Alexander SPH et al. (2020) A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic
research and development: IUPHAR Review 29. Br J Pharmacol, 177 (21): 4942-4966.
[PMID:32358833]
Cannalire R et al. (2020) Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19
Treatment: State of the Art and Future Opportunities. J Med Chem, [Epub ahead of print].
[PMID:33186044]
Cui J et al. (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol, 17 (3):
181-192. [PMID:30531947]
Desforges M et al. (2019) Human Coronaviruses and Other Respiratory Viruses: Underestimated
Opportunistic Pathogens of the Central Nervous System?. Viruses, 12 (1). [PMID:31861926]
Song Z et al. (2019) From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses, 11
(1). [PMID:30646565]
Zumla A et al. (2016) Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov,
15 (5): 327-47. [PMID:26868298]
Structural proteins
Other protein targets → SARS-CoV-2 → Structural proteins
Overview: The virus particle has four structural proteins. The envelope, membrane and spike proteins are on the viral surface, while the polybasic nucleoprotein enables the tight coiling of the viral
RNA.
Nomenclature Envelope protein Membrane glycoprotein Nucleoprotein Spike glycorprotein
Other names envelope small membrane protein, orf4 Membrane protein Nucleocapsid protein Spike protein
UniProt P0DTC4 P0DTC5 P0DTC9 P0DTC2
Function By similarity to other coronavirus E proteins,
SARS-CoV-2 E is predicted to constitute a single
transmembrane (potentially homopentameric) ion
channel with selectivity for monovalent cations over
monovalent anions [85, 119, 133, 139]
The membrane glycoprotein (M) is usually regarded
as the most abundant protein in the coronavirus
envelope. By similarity with other coronavirus M
proteins it is predicted to be essential for initiating
assembly of the viral envelope components [94]
The coronavirus nucleocapsid phosphoprotein (N,
or nucleoprotein) is highly basic and binds the viral
RNA as a dimeric entity [25] into nucleocapsids
which protect the viral genome, while also
providing access for replication when required
The spike protein extends
from the viral surface and
binds to the host cell surface
enzyme ACE2 to facilitate
viral entry into the cell
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Polyproteins
Other protein targets → SARS-CoV-2 → Polyproteins
Overview: The viral RNA encodes two overlapping polyproteins which are cleaved autocatalytically by intrinsic proteases (see below).
Nomenclature Replicase polyprotein 1a Replicase polyprotein 1ab
Other names Polyprotein 1a Polyprotein 1ab
UniProt P0DTC1 P0DTD1
Function The replicase polyprotein 1a (pp1a) encodes a set of 11 smaller proteins, including two proteases that are responsible for cleaving the
polyprotein chain into its component parts
The replicase polyprotein 1ab (pp1ab) encodes a
set of 16 smaller proteins (5 more than pp1a)
Comment: The component proteins are non-structural and are involved in the transcription and replication of viral proteins and RNA.
Proteases
Other protein targets → SARS-CoV-2 → Proteases
Nomenclature 3C-like (main) protease Papain-like protease
Other names 3c-like proteinase, SARS-CoV-2 Mpro, Chain A, 3c-like Proteinase, 3CL protease, Mpro, nsp5 non-structural protein 3, NS3, nsp3, PL-PRO
UniProt P0C6U8 P0DTC1
EC number 3.4.22.69 3.4.22.46
Function The 3C-like protease cleaves the two polyproteins encoded by the SARS-CoV-2 genome (pp1a and
pp1ab) into a range of non-structural proteins (nsp1-11 from pp1a; nsp1-16 from pp1ab). As these
component proteins play crucial roles in viral replication, the 3C-like protease is considered to be a
good molecular target for drug development. Small molecule 3C-like protease inhibitors would be
predicted to reduce viral replication [33, 85]
The papain-like protease is a domain within coronavirus Nsp3. Its proteolytic activity
cleaves three sites in the viral replicase polyprotein (recognition consensus sequence
LXGG↓XX) to release the three non-structural proteins Nsp1, Nsp2, and Nsp3 [40]. It has
additional non-proteolytic functions as part of the multicomponent replicase-transcriptase
complex [103]
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Nucleic acid turnover
Other protein targets → SARS-CoV-2 → Nucleic acid turnover
Nomenclature Non-structural protein 8 RNA-dependent RNA polymerase
Other names Nsp8 non-structural protein 12, nsp12
UniProt P0DTC8 P0DTD1
Function Coronavirus nsp8 proteins form a hexadecameric complex with nsp7
proteins (8 subunits of each) [48, 122]. This complex may participate in viral
replication by acting as a primase for de novo initiation of RNA synthesis
The conservation of RdRP catalytic domain between different RNA viruses endows inhibitors that were designed
against other viral pathogens with activity against the SARS coronaviruses. Viral RdRP is the molecular target of
nucleotide-based broad-spectrum antiviral compounds like remdesivir, tenofovir and ribavirin [33, 129, 141]
Other proteins
Other protein targets → SARS-CoV-2 → Other proteins
Nomenclature Protein 3a Protein 7a Protein 9b Non-structural protein 6 Non-structural protein 7b
Other names Orf3a Orf7a Orf9b, Accessory protein 9b, ORF-9b Nsp6 Accessory protein 7b, nsp7b
UniProt P0DTC3 P0DTC7 P0DTD2 P0DTC6 P0DTD8






The main function of the SARS-CoV
protein 7a appears to be disruption of the
host cell cycle and induction of
caspase-dependent apoptosis [120]. By
homology SARS-CoV-2 protein 7a is likely
to produce the same effect
SARS-CoV protein 9b is a virion-associated
accessory protein [120] that acts to block
the host’s ability to mount an antiviral
IFN-induced innate immune response [87].
By homology, 9b from SARS-CoV-2 would
be predicted to exhibit a similar function
Coronavirus nsp6 proteins limit
autophagosome expansion [21]. This
mechanism may favour coronavirus
infection by damaging
autophagosome-mediated delivery of viral
components to lysosomes for degradation
Protein 7b is a coronavirus
accessory protein. Experimental
evidence suggests that SARS-CoV
7b has some attenuating function
[87]. By homology, SARS-CoV-2 7b
is likely to have a similar function
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